Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

409 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
SARS-CoV-2 vaccination in the first year after hematopoietic cell transplant or chimeric antigen receptor T cell therapy: A prospective, multicenter, observational study (BMT CTN 2101).
Hill JA, Martens MJ, Young JH, Bhavsar K, Kou J, Chen M, Lee LW, Baluch A, Dhodapkar MV, Nakamura R, Peyton K, Howard DS, Ibrahim U, Shahid Z, Armistead P, Westervelt P, McCarty J, McGuirk J, Hamadani M, DeWolf S, Hosszu K, Sharon E, Spahn A, Toor AA, Waldvogel S, Greenberger LM, Auletta JJ, Horowitz MM, Riches ML, Perales MA. Hill JA, et al. Among authors: mccarty j. medRxiv [Preprint]. 2024 Jan 25:2024.01.24.24301058. doi: 10.1101/2024.01.24.24301058. medRxiv. 2024. PMID: 38343800 Free PMC article. Preprint.
Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of FLT3.
Levis MJ, Hamadani M, Logan B, Jones RJ, Singh AK, Litzow M, Wingard JR, Papadopoulos EB, Perl AE, Soiffer RJ, Ustun C, Ueda Oshima M, Uy GL, Waller EK, Vasu S, Solh M, Mishra A, Muffly L, Kim HJ, Mikesch JH, Najima Y, Onozawa M, Thomson K, Nagler A, Wei AH, Marcucci G, Geller NL, Hasabou N, Delgado D, Rosales M, Hill J, Gill SC, Nuthethi R, King D, Wittsack H, Mendizabal A, Devine SM, Horowitz MM, Chen YB; BMT-CTN 1506/MORPHO Study Investigators. Levis MJ, et al. J Clin Oncol. 2024 May 20;42(15):1766-1775. doi: 10.1200/JCO.23.02474. Epub 2024 Mar 12. J Clin Oncol. 2024. PMID: 38471061 Free PMC article. Clinical Trial.
Anti-thymocyte globulin for conditioning in matched unrelated donor hematopoietic cell transplantation provides comparable outcomes to matched related donor recipients.
Portier DA, Sabo RT, Roberts CH, Fletcher DS, Meier J, Clark WB, Neale MC, Manjili MH, McCarty JM, Chung HM, Toor AA. Portier DA, et al. Among authors: mccarty jm. Bone Marrow Transplant. 2012 Dec;47(12):1513-9. doi: 10.1038/bmt.2012.81. Epub 2012 May 14. Bone Marrow Transplant. 2012. PMID: 22580767 Free PMC article.
Three-Year Outcomes in Recipients of Mismatched Unrelated Bone Marrow Donor Transplants Using Post-Transplantation Cyclophosphamide: Follow-Up from a National Marrow Donor Program-Sponsored Prospective Clinical Trial.
Shaw BE, Jimenez-Jimenez AM, Burns LJ, Logan BR, Khimani F, Shaffer BC, Shah NN, Mussetter A, Tang XY, McCarty JM, Alavi A, Farhadfar N, Jamieson K, Hardy NM, Choe H, Ambinder RF, Anasetti C, Perales MA, Spellman SR, Howard A, Komanduri KV, Luznik L, Norkin M, Pidala JA, Ratanatharathorn V, Confer DL, Devine SM, Horowitz MM, Bolaños-Meade J. Shaw BE, et al. Among authors: mccarty jm. Transplant Cell Ther. 2023 Mar;29(3):208.e1-208.e6. doi: 10.1016/j.jtct.2022.12.017. Epub 2022 Dec 27. Transplant Cell Ther. 2023. PMID: 36584941 Free PMC article.
Favorable outcomes in patients with high donor-derived T cell count after in vivo T cell-depleted reduced-intensity allogeneic stem cell transplantation.
Toor AA, Sabo RT, Chung HM, Roberts C, Manjili RH, Song S, Williams DC Jr, Edmiston W, Gatesman ML, Edwards RW, Ferreira-Gonzalez A, Clark WB, Neale MC, McCarty JM, Manjili MH. Toor AA, et al. Biol Blood Marrow Transplant. 2012 May;18(5):794-804. doi: 10.1016/j.bbmt.2011.10.011. Epub 2011 Oct 17. Biol Blood Marrow Transplant. 2012. PMID: 22005648 Free PMC article. Clinical Trial.
Fludarabine-based conditioning for marrow transplantation from unrelated donors in severe aplastic anemia: early results of a cyclophosphamide dose deescalation study show life-threatening adverse events at predefined cyclophosphamide dose levels.
Tolar J, Deeg HJ, Arai S, Horwitz M, Antin JH, McCarty JM, Adams RH, Ewell M, Leifer ES, Gersten ID, Carter SL, Horowitz MM, Nakamura R, Pulsipher MA, Difronzo NL, Confer DL, Eapen M, Anderlini P. Tolar J, et al. Among authors: mccarty jm. Biol Blood Marrow Transplant. 2012 Jul;18(7):1007-11. doi: 10.1016/j.bbmt.2012.04.014. Epub 2012 Apr 27. Biol Blood Marrow Transplant. 2012. PMID: 22546497 Free PMC article. Clinical Trial.
Peripheral-blood stem cells versus bone marrow from unrelated donors.
Anasetti C, Logan BR, Lee SJ, Waller EK, Weisdorf DJ, Wingard JR, Cutler CS, Westervelt P, Woolfrey A, Couban S, Ehninger G, Johnston L, Maziarz RT, Pulsipher MA, Porter DL, Mineishi S, McCarty JM, Khan SP, Anderlini P, Bensinger WI, Leitman SF, Rowley SD, Bredeson C, Carter SL, Horowitz MM, Confer DL; Blood and Marrow Transplant Clinical Trials Network. Anasetti C, et al. Among authors: mccarty jm. N Engl J Med. 2012 Oct 18;367(16):1487-96. doi: 10.1056/NEJMoa1203517. N Engl J Med. 2012. PMID: 23075175 Free PMC article. Clinical Trial.
Reduced-intensity allogeneic transplantation provides high event-free and overall survival in patients with advanced indolent B cell malignancies: CALGB 109901.
Shea T, Johnson J, Westervelt P, Farag S, McCarty J, Bashey A, Isola L, Baxter-Lowe LA, Kelly M, Owzar K, Linker C; Cancer and Leukemia Group B. Shea T, et al. Among authors: mccarty j. Biol Blood Marrow Transplant. 2011 Sep;17(9):1395-403. doi: 10.1016/j.bbmt.2011.01.016. Epub 2011 Feb 3. Biol Blood Marrow Transplant. 2011. PMID: 21296675 Free PMC article. Clinical Trial.
Micro-Coring: A Novel Approach to Perioral Rejuvenation.
Carruthers KH, Vyas K, Remy K, McCarty JC, Austen WG Jr. Carruthers KH, et al. Among authors: mccarty jc. Aesthet Surg J. 2024 May 31:sjae120. doi: 10.1093/asj/sjae120. Online ahead of print. Aesthet Surg J. 2024. PMID: 38820175
409 results